Point Biomedical is developing a third-generation ultrasound contrast agent before second-generation agents have been successfully adopted. But as a small company, it must make choices about what it can realistically handle and what it can't--thus it is purusing a second business in acoustic drug delivery, but passing on urological and surgical applications of its biomaterials technology.
By David Cassak
If you don't know where you're going, any road will take you there." It's one of the givens of effective...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.